Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and Corcept Therapeutics (NASDAQ:CORT – Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.
Institutional & Insider Ownership
98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 20.8% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Madrigal Pharmaceuticals and Corcept Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Madrigal Pharmaceuticals | $958.40 million | 10.52 | -$288.28 million | ($12.87) | -34.14 |
| Corcept Therapeutics | $761.41 million | 4.76 | $99.65 million | $0.82 | 41.51 |
Corcept Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Madrigal Pharmaceuticals has a beta of -0.97, meaning that its stock price is 197% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.
Profitability
This table compares Madrigal Pharmaceuticals and Corcept Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Madrigal Pharmaceuticals | -30.08% | -43.76% | -24.88% |
| Corcept Therapeutics | 12.96% | 15.19% | 11.93% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Madrigal Pharmaceuticals and Corcept Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Madrigal Pharmaceuticals | 1 | 3 | 12 | 1 | 2.76 |
| Corcept Therapeutics | 2 | 2 | 4 | 0 | 2.25 |
Madrigal Pharmaceuticals currently has a consensus target price of $685.31, suggesting a potential upside of 55.99%. Corcept Therapeutics has a consensus target price of $77.17, suggesting a potential upside of 126.69%. Given Corcept Therapeutics’ higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Madrigal Pharmaceuticals.
Summary
Corcept Therapeutics beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
